Stock ATAI ATAI LIFE SCIENCES N.V.
Add to a list
To use this feature you must be a member
Log inSign up

All News Atai Life Sciences N.V.

Equities

ATAI

NL0015000DX5

Real-time Estimate Cboe BZX
Other stock markets
 12:05:36 2024-05-03 pm EDT 		5-day change 1st Jan Change
2.085 USD -2.11% Intraday chart for Atai Life Sciences N.V. +7.25% +46.81%
Apr. 24 Atai Life Sciences Announces Dosing of First Patient in Part 2 of Beckley Psytech?s Phase 2a Study Exploring BPL-003 Adjunctive to SSRIs in Patients with Treatment Resistant Depression CI
Apr. 17 Clarify Pharma to change name to File Forge Technology AN

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Atai Life Sciences Announces Dosing of First Patient in Part 2 of Beckley Psytech's Phase 2a Study Exploring BPL-003 Adjunctive to SSRIs in Patients with Treatment Resistant Depression
AQ
Atai Life Sciences Announces Dosing of First Patient in Part 2 of Beckley Psytech’s Phase 2a Study Exploring BPL-003 Adjunctive to SSRIs in Patients with Treatment Resistant Depression
GL
Atai Life Sciences Announces Dosing of First Patient in Part 2 of Beckley Psytech?s Phase 2a Study Exploring BPL-003 Adjunctive to SSRIs in Patients with Treatment Resistant Depression
CI
Clarify Pharma to change name to File Forge Technology
AN
Atai Life Sciences Announces the Publication of Beckley Psytech’s Phase 1 Study of BPL-003 in the Journal of Psychopharmacology
GL
Atai Life Sciences Announces the Publication of Beckley Psytech?s Phase 1 Study of BPL-003 in the Journal of Psychopharmacology
CI
Momentum Stocks Alert: DYAI, KAVL, VTAK, NKLA, ATAI Demonstrate Financial Growth and Strategic Advancements
AQ
Sector Update: Health Care Stocks Softer Late Afternoon
MT
Atai Life Sciences Shares Rise Following Maxim Upgrade
MT
Maxim Upgrades Atai Life Sciences to Buy From Hold, Price Target is $6
MT
HC Wainwright Cuts Atai Life Sciences Price Target to $15 From $20, Maintains Buy Rating
MT
Atai Life Sciences Announces Positive Initial Results from Beckley Psytech's Phase 2a Open Label Study of BPL-003 in Treatment Resistant Depression
AQ
Atai Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate and Clinical Highlights
GL
Atai Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate and Clinical Highlights
AQ
Atai Life Sciences N.V. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Atai Life Sciences N.V. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
CI
Atai Life Sciences Announces Positive Initial Results from Beckley Psytech’s Phase 2a Open Label Study of BPL-003 (Intranasal 5-MeO-DMT) in Treatment Resistant Depression
GL
Atai Life Sciences Announces Positive Initial Results from Beckley Psytech?s Phase 2a Open Label Study of BPL-003 (Intranasal 5-MeO-DMT) in Treatment Resistant Depression
CI
Atai Life Sciences advances VLS-01 for treatment-resistant depression
AQ
IntelGenx Subsidiary Signs Third Amended, Restated Loan Agreement With atai Life Sciences
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ATAI Stock
  4. News Atai Life Sciences N.V.